SimBioSys, which specializes in spatial biophysics and artificial intelligence (AI), has recently entered into a strategic collaboration with Mayo Clinic to advance digital precision medicine solutions for breast cancer patients. The collaboration will develop cloud-based clinical software tools that will guide the decision-making process for early-stage breast cancer patients, covering personalized surgical planning, treatment strategies, drug selection, and risk assessment.
According to the two parties, the collaboration intends to address the evolving landscape of breast cancer treatment by tailoring care to individual patients, optimizing therapies, and improving quality of life without compromising outcomes.
The collaboration includes Mayo Clinic physicians Judy C. Boughey, M.D., and Matthew Goetz, M.D., who are actively contributing to SimBioSys’s clinical advisory team. Their expertise in breast and melanoma surgical oncology and translational Research, respectively, will support the ongoing development and validation of clinical software tools.
Under the deal, SimBioSys has gained access to data from the Mayo Clinic-led BEAUTY clinical trial (NCT02022202) and is utilizing AI and data science to unlock spatial biophysical insights. These insights aim to assist clinicians in tailoring treatment plans for each patient based on their unique characteristics. SimBioSys is conducting simulations using previously acquired data and validating the predictive accuracy of its platform, TumorSightTM, through in-silico scenario analysis guided by Mayo Clinic experts.
TumorSight, a cloud-based platform currently under FDA review, is SimBioSys’s flagship product. It utilizes a patient’s standard of care DCE-MRI imaging to create a custom 3D digital model of their tumor. This innovative tool provides surgical oncologists with 3D spatial visualizations of breast cancer, enabling more effective surgical planning and patient consultations. The platform generates clear 3D “digital twin” renderings that display the tumor in the context of auto-segmented anatomical structures, such as skin, blood vessels, chest, fat, glands, and heart.
“In the crowded world of genomics, new approaches have many barriers to becoming a new standard of care,” says Tushar Pandey, co-founder and CEO of SimBioSys. “SimBioSys complements current precision medicine techniques while only relying on readily available and previously acquired datasets such as imaging. We are delighted to collaborate with Mayo Clinic as we bring our innovative technology to patients.”
Mayo Clinic, recognized as a Comprehensive Cancer Center by the National Cancer Institute, is one of the 45 NCI-designated comprehensive centers in the United States. Notably, Mayo Clinic has a financial interest in the technology mentioned in the collaboration and plans to utilize any revenue generated to support its not-for-profit mission in patient care, education, and research.
